Article
Microbiology
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Aminah Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Yazed Saleh Alsowaida
Summary: This study aimed to compare the effectiveness and safety of C-T and CAZ-AVI in treating infections caused by resistant P. aeruginosa. The results showed no significant differences between C-T and CAZ-AVI in terms of in-hospital mortality, 30-day mortality, clinical cure, and safety. Both drugs can be potential options for the treatment of MDR P. aeruginosa infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Thamer A. Almangour, Ahmad Aljabri, Mohammed Al Musawa, Abdullah Almohaizeie, Sara Almuhisen, Nader Damfu, Awaly Alfozan, Basem M. Alraddadi, Majda Alattas, Mohammed Qutub, Abrar F. Alhameed, Malik Khuwaja, Ahlam Alghamdi, Khalifa M. Binkhamis, Wafa Alfahad, Fatimah S. AIShahrani
Summary: This study compared the safety and effectiveness of ceftolozane-tazobactam (C-T) to colistin-based regimen for treating infections caused by multidrug-resistant Pseudomonas aeruginosa. The results showed that C-T was associated with a higher rate of clinical cure and a lower rate of acute kidney injury compared to colistin. Therefore, the preferential use of C-T for treating these infections is supported.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2022)
Article
Immunology
Delaney E. Hart, Jason C. Gallagher, Laura A. Puzniak, Elizabeth B. Hirsch
Summary: This study evaluated treatment and clinical outcomes of 69 immunocompromised patients receiving ceftolozane/tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Clinical cure was achieved in 68% of patients, while 19% mortality rate was observed within 30 days.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Review
Infectious Diseases
Marco Fiore, Antonio Corrente, Maria Caterina Pace, Aniello Alfieri, Vittorio Simeon, Mariachiara Ippolito, Antonino Giarratano, Andrea Cortegiani
Summary: According to this systematic review and meta-analysis, C/T combination therapy is more effective in treating severe infections compared to C/T monotherapy, resulting in a reduction in patient mortality. However, there were no significant differences between C/T combination therapy and C/T monotherapy in terms of clinical improvement and microbiological cure.
Article
Infectious Diseases
Dana J. Holger, Nicholas S. Rebold, Sara Alosaimy, Taylor Morrisette, Abdalhamid Lagnf, Ana Christine Belza, Ashlan J. Kunz Coyne, Amer El Ghali, Michael P. Veve, Michael J. Rybak
Summary: This retrospective analysis compared the clinical outcomes between patients who received Ceftolozane-tazobactam (C/T) treatment and the best alternative therapy for multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa lower respiratory tract infections (LRTIs). The results showed that C/T treatment was associated with a significantly reduced clinical failure rate compared to the best alternative therapy, suggesting that it is a safe and effective therapeutic regimen for MDR and XDR P. aeruginosa LRTI.
INFECTIOUS DISEASES AND THERAPY
(2022)
Article
Infectious Diseases
James A. Karlowsky, Sibylle H. Lob, Fakhar Siddiqui, Brune Akrich, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Stephen P. Hawser, Daniel F. Sahm
Summary: The study found that most Pseudomonas aeruginosa isolates in Western Europe (93.3%) were susceptible to ceftolozane/tazobactam, indicating it as an important treatment option for multidrug-resistant infections.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Christian M. Gill, David P. Nicolau, RACE PA Global Study Grp
Summary: This study evaluated the genotypic and ceftazidime/avibactam-susceptibility profiles of ceftolozane/tazobactam-non-susceptible, MBL-negative Pseudomonas aeruginosa. The results showed that ceftazidime/avibactam remained active against the majority of ceftolozane/tazobactam-non-susceptible, MBL-negative Pseudomonas aeruginosa.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Article
Infectious Diseases
Barbara Balandin, Daniel Ballesteros, Rafael Ruiz de Luna, Loreto Lopez-Vergara, Vicente Pintado, Milagros Sancho-Gonzalez, Cruz Soriano-Cuesta, Maria Jose Perez-Pedrero, Maria Jose Asensio-Martin, Inamculada Fernandez-Simon, Diego Rodriguez-Serrano, Alberto Silva, Marta Chicot, Reyes Iranzo, Fernando Martinez-Sagasti, Ana Royuela
Summary: This study assessed the efficacy of ceftolozane-tazobactam (C/T) in treating Pseudomonas aeruginosa infections in critically ill patients. Results showed that C/T was effective in treating severe infections, with outcomes mainly related to infection severity. High-dose C/T or combination therapy with other antibiotics did not show additional benefits.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2021)
Article
Microbiology
Abigail M. Rubio, Ellen G. Kline, Chelsea E. Jones, Liang Chen, Barry N. Kreiswirth, M. Hong Nguyen, Cornelius J. Clancy, Vaughn S. Cooper, Ghady Haidar, Daria Van Tyne, Ryan K. Shields
Summary: In this study, we compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates before and after exposure to ceftolozane-tazobactam and found treatment-emergent mutations in the AmpC gene, which were associated with altered resistance patterns. However, some ceftolozane-tazobactam-resistant isolates with AmpC mutations remained susceptible to imipenem-relebactam.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Microbiology
Lina Rivas, Manuel Alcalde-Rico, Jose R. W. Martinez, Maria Victoria Moreno, Pamela Rojas, Aniela Wozniak, Patricia Garcia, Jorge Olivares-Pacheco, William R. Miller, Cesar A. Arias, Ayesha Khan, Jose M. Munita
Summary: This study evaluated the performance of different antimicrobial susceptibility testing methods in non-carbapenemase producing-carbapenem-resistant Pseudomonas aeruginosa, revealing a significant decrease in performance when testing isolates resistant to all beta-lactams.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Aisling R. Caffrey, Haley J. Appaneal, J. Xin Liao, Emily C. Piehl, Vrishali Lopes, Ryan J. Dillon, Laura A. Puzniak, Kerry L. LaPlante
Summary: This study compares the effectiveness of ceftolozane/tazobactam treatment with aminoglycoside or polymyxin treatment in hospitalized patients. Patients treated with ceftolozane/tazobactam had a significantly lower inpatient mortality rate compared to those treated with aminoglycoside or polymyxin.
Article
Microbiology
C. Weber, T. Schultze, S. Goettig, J. Kessel, A. Schroeder, M. Tietgen, S. Besier, T. Burbach, S. Haeussler, T. A. Wichelhaus, D. Hack, V. A. J. Kempf, M. Hogardt
Summary: The study demonstrates that cefiderocol is the most effective antipseudomonal beta-lactam agent for multidrug-resistant (MDR) Pseudomonas aeruginosa, with susceptibility rates of 46.6%, 48.4%, and 97.3% for ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol, respectively. The most prevalent sequence type was ST235 (24.7%), followed by ST244, ST175, and ST233, all of which belong to the top 10 high-risk clones with worldwide distribution. Surveillance studies should pay special attention to MDR and highly virulent VIM- and ExoU-producing variants of ST235. Cefiderocol is the preferred treatment option for infections caused by carbapenemase-producing MDR P. aeruginosa, and it has shown favorable outcomes in complicated urinary tract infections and hospital-acquired pneumonia.
MICROBIOLOGY SPECTRUM
(2022)
Review
Biology
Luca Gregorio Giaccari, Maria Caterina Pace, Maria Beatrice Passavanti, Francesca Gargano, Caterina Aurilio, Pasquale Sansone
Summary: Ceftolozane/tazobactam (C/T) may be a valid therapeutic option for treating multidrug-resistant Pseudomonas aeruginosa infections, with high clinical success rates and good tolerability, making it feasible to use in various comorbidities.
Article
Microbiology
Maria Milagro Montero, Sandra Domene-Ochoa, Carla Lopez-Causape, Inmaculada Lopez-Montesinos, Sonia Luque, Luisa Sorli, Nuria Campillo, Eduardo Padilla, Nuria Prim, Lorena Ferrer Alapont, Santiago Grau, Antonio Oliver, Juan P. Horcajada
Summary: This study compared the efficacy of intermittent, extended, and continuous infusion of ceftolozane-tazobactam (C/T) and found that continuous infusion achieved the best results in treating infections caused by extensively drug-resistant (XDR) P. aeruginosa isolates. It was the only regimen with bactericidal activity against all tested isolates, indicating the potential of continuous C/T infusion as a treatment option.
MICROBIOLOGY SPECTRUM
(2022)
Article
Infectious Diseases
Woraphot Tantisiriwat, Jirawat Buppanharun, Chatchai Ekpanyaskul, Kwanchai Onruang, Thitiya Yungyuen, Pattarachai Kiratisin, Somchai Santiwatanakul
Summary: This study aimed to assess the in vitro activity of ceftolozane-tazobactam (C-T) against resistant Pseudomonas aeruginosa (PA) and investigate the resistant genes in PA strains that were resistant to C-T.
